Építés alatt – nem éles oldal
Belépés
Csak meghívásos3. fázis

Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients

A legfontosabb adatok

Ki végzi
Mahidol University
Hol
Bangkok (Thaiföld)A helyszín megnézése
Azonosító
Állapot
Csak meghívásos
Fázis
3. fázis
Résztvevők
30 fő, tervezett
Kezdés
2023. nov. 13.
Tervezett befejezés
2025. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Branched-chain amino acid
A regiszteradat frissítve
2025. szeptember 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with cirrhosis (scarring of the liver) from any cause, with fluid in the belly (ascites) and low blood albumin. Participants take branched-chain amino acid drinks twice a day for 12 weeks.

Életkor
18 to 85 years
Nem
All sexes
A betegség stádiuma
Cirrhosis of any cause with ascites that a doctor can detect on examination.
Korábbi kezelés
People cannot join if they had large volume fluid drainage from the belly (>5 liters) with albumin into a vein on the day of enrollment, or albumin into a vein every 1-2 weeks in the last one month.
Biomarker vagy leletérték
Serum albumin < 3 g/dL

A részvétel fő kizáró okai

  • Liver cancer (hepatocellular carcinoma) outside the Milan criteria
  • Bleeding in the gut or belly fluid infection (SBP) in the last 3 months, or sudden worsening of chronic liver failure (ACLF)
  • Uncontrolled long-term illness, such as heart failure NYHA 3-4, kidney failure needing dialysis, or COPD Gold D
  • Past liver or kidney transplant, or living with HIV
  • Pregnant or breastfeeding, or past amputation above the knee

A regiszter feltételei, szó szerint

Mind a 7 feltétel megnézéseKevesebb

Ki vehet részt

  • Cirrhotic patients of all etiology with aged of 18-85 years
  • Clinically detectable ascites
  • Serum albumin < 3 g/dL

Ki nem vehet részt

  • Patients with history of gastrointestinal bleeding and spontaneous bacterial peritonitis (SBP) within the last 3 months
  • Patients with acute on chronic liver failure (ACLF)
  • Patients with uncontrollable chronic comorbidities, including chronic heart failure in NYHA stages 3-4, end stage kidney disease requiring dialysis, and chronic obstructive pulmonary disease Gold D; 5 .Patients who have undergone liver or kidney transplant. 6. Patients with Human Immunodeficiency Virus (HIV). 7. Pregnant or lactating patients. 8. Patients who have undergone large volume paracentesis (>5 liters) with intravenous albumin administration on the day of study enrollment. 9. Patients with a history of above-knee amputation surgery. 10. Patients with a history of receiving intravenous albumin administration every 1-2 weeks within the last one month
  • Patients with hepatocellular carcinoma outside the Milan criteria

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 85 év között vagy?

Helyszínek itt: Thaiföld

  • Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandBangkok, ThaiföldCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to compare the nutritional parameters after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL.

A teljes eredeti leírásKevesebb

The main questions it aims to answer are:

1. Would thigh muscle thickness change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL? 2. Would triceps skin fold thickness, mid-arm circumferences, mid-arm muscle circumferences, skeletal muscle mass, appendicular skeletal muscle mass, skeletal muscle index and fat mass change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL? 3. Would handgrip strength change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL? 4. Would serum albumin change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL? 5. Would score for cirrhotic severity such as Model for End-Stage Liver Disease-Sodium Score (MELD-Na score) and Child Turcotte Pugh Score change after 12-week supplementation of branched-chain amino acids in cirrhotic patients with ascites and serum albumin less than 3 g/dL?

Participants will be asked to do following tasks:

1. Participants will be asked for basic information such as age, place of residence, and contact telephone number. 2. Participants will undergo measurements of weight, height, body mass index, skinfold thickness on the arms, circumference of the arms and legs, muscle mass, and body fat content using a body composition analyzer, both at the beginning and end of the research study. 3. Participants will perform grip strength measurements, at both the beginning and end of the research study. 4. Participants will undergo laboratory tests, including a complete blood count, liver and kidney function tests, blood clotting factors, and blood mineral levels, with a total blood volume of approximately 15 milliliters (1 tablespoon), collected twice during the study (at the beginning and end). 5. Participants will be administered supplements containing branched-chain amino acids (BCAA) twice a day for a total of 12 weeks. 6. Participants will be appointed for follow-up during the study, totaling 2 appointments at weeks 4 and 12. Side effects related to medication will be asked. 7. Participants will undergo ultrasound measurements of the right thigh to assess thigh muscle thickness, both at the beginning and end of the research study. 8. Participants will will complete questionnaires to assess your overall quality of life twice, both at the beginning and end of the research study.

A vizsgálat csoportja

  • branched-chain amino acidA vizsgált kezelés

    Oral branched-chain amino acid (BCAA) is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients: a Pilot Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06121479: ki vehet részt
A regiszteradat frissítve
2025. szeptember 29.